Miami, United States
Ostro, operating since 2019 and headquartered in the United States, positions itself at the intersection of Health Care, Information Technology, and Pharmaceuticals. The company is notably recognized for its slogan, "Making medicine make sense: agentic AI omnichannel platform for better HCP and consumer engagement 🚀".
As a premier AI engagement platform, Ostro is trusted by most of the top 20 pharmaceutical companies, as well as a number of emerging and mid-size manufacturers. It provides life science brands with tools to engage providers and patients seamlessly through a variety of channels including web, email, SMS, and voice. By orchestrating millions of personalized interactions, Ostro aims to foster measurable behavioral changes and improved healthcare outcomes.
In its latest funding round, Ostro secured a $45.00M Series B investment on 15 April 2022 from a robust roster of investors, including RRE Ventures, Susa Ventures, Founders Fund, Bling Capital, Caffeinated Capital, Greycroft, Trust Ventures, and Byers Capital. This strategic backing underscores confidence in Ostro's growth trajectory and its role in reshaping pharmaceutical engagements.
